1 A Comparative Study of Target Reconstruction of Ultra-High-Resolution

2 CT for Patients with Corona-Virus Disease 2019 (COVID-19)

3 Shao-mao Lv^{1,2}, Yu Lin¹, Jiang-he Kang¹, Shao-yin Duan¹, Wei-guoZhang^{2*}, Jin-an Wang¹

4 ***Correspondence** wgzhang01@163.com

¹Department of Radiology, Zhongshan Hospital, Xiamen University, Xiamen 361004, China

⁶ ²Department of Radiology, Daping Hospital, Army Medical University, Chongqing 400010, China

7

8 Abstract

9 **Background:** The corona-virus disease 2019 (COVID-19) pandemic has caused a serious public health risk. Compared with conventional high-resolution CT (C-HRCT, matrix 512), LO ultra-high resolution CT (U-HRCT, matrix 1024) can increase the effective pixel per unit Ι1 volume by about 4 times. Our study is to evaluate the value of target reconstruction of Uι2 HRCT in the accurate diagnosis of COVID-19. L3 Methods: A total of 13 COVID-19 cases, 44 cases of other pneumonias, and 6 cases of ι4 ground-glass nodules were retrospectively analyzed. The data were categorized into groups ۱5 A (C-HRCT) and B (U-HRCT), following which iDose⁴-3 and iDose⁴-5 were used for target ۱6 reconstruction, respectively. CT value, noise, and signal-to-noise ratio (SNR) in different ι7 reconstructed images were measured. Two senior imaging doctors scored the image quality ٤8 and the structure of the lesions on a 5-point scale. Chi-square test, variance analysis, and ٤9 20 binarylogistic regression analysis were used for statistical analysis.

21	Results: U-HRCT image can reduce noise and improve SNR with an increase of the iterative
22	reconstruction level. The SNR of U-HRCT image was lower than that of the C-HRCT image
23	of the same iDose ⁴ level, and the noise of U-HRCT was higher than that of C-HRCT image;
<u>2</u> 4	the difference was statistically significant ($P < 0.05$). Logistic regression analysis showed
25	thatperipleural distribution, thickening of blood vessels and interlobular septum, and crazy-
26	paving pattern were independent indictors of the COVID-19 on U-HRCT. U-HRCT was
27	superior to C-HRCT in showing the blood vessels, bronchial wall, and interlobular septum in
28	the ground-glass opacities; the difference was statistically significant ($P < 0.05$).
29	Conclusions: Peripleural distribution, thickening of blood vessels and interlobular septum,
30	and crazy-paving pattern on U-HRCT are favorable signs for COVID-19. U-HRCT is
31	superior to C-HRCT in displaying the blood vessels, bronchial walls, and interlobular
32	septum for evaluating COVID-19.
33	Keywords: U-HRCT, 1024 matrix, Target Reconstruction, COVID-19
34	

35 Background

The outbreak of the novel corona-virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide[1]. The COVID-19 pandemic has caused a serious public health risk. COVID-19 is characterized by high infectivity and a typical clinical features[2]. The diagnosis of COVID-19 relied on virus nucleic acid detection with a high false negative rate [3].

- High resolution computed tomography (HRCT) is a convenient and accessible method for early
 screening and diagnosis of viral pneumonia [4]. Typical chest HRCT findings for COVID-19 included the
 ground glass lesions, enlarged blood vessels and "crazy paving signs" [5].
- +3 Compared with conventional high-resolution CT (C-HRCT, with matrix of 512×512), ultra-high

- 14 resolution CT (U-HRCT, with matrix of 1024×1024) can increase the effective pixel per unit volume by
- about 4 times in the same field of view (FOV) [6]. The UHRCT can not only reveal each ground glass lesion
- ¹⁶ with sub-millimeter precision, but also quantify the extent and severity of each lesion[7,8].

Thus, the purpose of this study was to evaluate the value of U-HRCT in the quantitative assessment ofCOVID-19 and to compare the radiological patterns of U-HRCT and C-HRCT.

19 Methods

50 **Patients**

The study conducted a retrospective analysis of 63 suspected COVID-19 patients examined using CT at our hospital between January 22 and February 15, 2020. The patients included 35 males and 28 females aged between 6–69 years, with an average age of (35 ± 10.6) years. Among them, 13 cases were confirmed as COVID-19, 44 cases were diagnosed with other pneumonias, and 6 cases were diagnosed with ground-glass opacities.

56 CT scans

The Ingenuity CT scanner (Philips Healthcare, the Netherlands) was used. The patient was placed in a supine position with breath hold during the scan. The scanning range was from the apex to the base of the lung. Scanning parameters included the following: tube voltage120 kV; mAs: DoseRight Index 15–20; collimation64 \times 0.625 mm; pitch, 1.2; slice thickness 2 mm; interval 2 mm; FOV 35 cm. The raw data acquired were categorized into groups A (512 matrix) and B (1024 matrix). Each group was reconstructed using iDose⁴-3 and iDose⁴-5 iterative reconstructions within the same small FOV with a slice thickness and interval of 1 mm.

54 Image analysis

55 Analysis of typical signs

56 A group of images was selected at random, and the CT data of all patients were evaluated by two

radiologists with over 10 years of experience while blinded to each other's results. The assessment of lesions included the following: (1) distribution (distance from the pleura); (2) number(single or multiple); (3) density (pure ground-glass opacities, mixed ground-glass opacities, and consolidation); and (4) Internal structure (air bronchograms sign, vascular thickening, interlobular septal thickening, and crazy-paving patterns in the lesions).

¹² Objective scoring of image quality

73 Each group of images was transferred to the Philips IntelliSpace Portal workstation. The relevant 74 information was locked, and the iDose3 and iDose5 groups of images were reconstructed, measured, and 75 evaluated in the fixed lung window (window width 1600 HU, window level -600 HU). A region of interest 76 (ROI) (50 mm² approximate area) in the lung tissue at the level of the tracheal carina and left atrium was 17 selected (avoiding lung markings and lesion areas), the standard deviation (SD) was measured, and the average CT value was recorded to calculate the signal-to-noise ratio (SNR). Each ROI was measured three 78 79 times, and the average value was recorded. SNR = CTn/SDn, where CTn and SDn are the average CT and 30 SD values of the lung tissue, respectively. The SD value is the objective noise of the image.

31 Subjective scoring of image quality

32 The two radiologists, with over 10 years of work experience, quantitatively evaluated image quality under 33 the same magnification ratio. Differences in opinion were resolved by consensus. Image quality was scored 34 on a 5-point scale. The evaluation included image noise, presentation of the bronchovascular bundles 2 cm 35 from the pleura, presentation of the lesion and its internal structure, and feasibility of diagnosis. For scoring, 5 points: clear lesion and vascular structure with no artifacts; 4 points: acceptable lesion and vascular 36 37 structure with a small number of artifacts; 3 points: unclear lesion and vascular structure with more artifacts, 38 but diagnosis was unaffected; 2 points: unclear lesion and vascular structure with significant artifacts 39 making diagnosis unsatisfactory; 1 point: unclear lesion and vascular structure, and multiple types of)0 artifacts making diagnosis unsatisfactory.

)1 Statistical analysis

)2 The SPSS 22.0 software was used for analysis. Measurement data were expressed as $x \pm s$. ANOVA was ЭЗ performed on the SD and SNR values of each group of images. Differences with p < 0.05 were considered)4 statistically significant. Pairwise comparisons between the groups were performed. Count data were expressed as number of cases and percentage, and the Pearson χ^2 test was used for comparisons between)5 Э6 groups. Binary logistic regression was used for analysis of independent risk factors of CT diagnosis of)7 COVID-19. The receiver operating characteristic (ROC) curve was used for analysis of the sensitivity and)8 specificity of risk factors of COVID-19 prediction. Medcalc software (version 17.6) was used for)9 comparison and plotting the efficacy of the area under the curve (AUC). Differences with p < 0.05 were)0 considered statistically significant.

)1 **Results**

)2 Clinical characteristics

A total of 63 cases were included in the study. Some patients underwent CT re-examinations, and a total of
75 groups of CT data were obtained for analysis. The 13 confirmed cases of COVID-19 were primarily
imported cases or had a history of contact (12/13). There were 59 cases of other types of pneumonias and 6
cases of ground-glass nodules.

)7 CT presentation

)8 Analysis of the CT presentation of the lesions included the distribution and density of lesions and the)9 condition within the lesions (Table 1). With respect to lesion distribution, COVID-19 lesions were mainly LO distributed within 2 cm of the pleura (87.5%), whereas lesion distribution was non-specific in other ι1 pneumonias. COVID-19 lesions were mainly pure (75%) or mixed (18.75%) ground-glass opacities, Ι2 whereas lesions from other pneumonias were mainly of mixed density (64.41%). Air bronchograms, L3 vascular thickening, interlobular septal thickening, and crazy-paving signs were present in COVID-19 ι4 lesions, at frequencies of 81.5%, 87.5%, 87.5%, and 93.75%, respectively. Air bronchograms were also ۱5 common in non-COVID-19 pneumonias (57.63%). The differences in all radiological signs, except the ۱6 number of lesions, were statistically significant between COVID-19 and non- COVID-19 lesions (p < 0.05).

17 Logistic regression analysis

Lesion distribution and density, and structural features within the lesion were entered into a logistic regression analysis model to evaluate the independent risk factors of CT diagnosis of COVID-19. The analysis showed that lesion distribution, vascular thickening, interlobular septal thickening, and crazypaving patterns had value for COVID-19 diagnosis (OR = 0.001, p = 0.003; OR = 43.212, p = 0.008; OR = 25.962, p = 0.022; OR = 258.081, p = 0.0001, respectively). However, lesion density and air bronchograms had minimal predictive value, and there was no statistically significant difference between two groups (Table 2).

25 ROC analysis

26 ROC curve analysis showed that the AUC of lesion distribution, vascular thickening, interlobular septal

thickening, and crazy-paving patterns were 0.887, 0.870, 0.813, and 0.926, respectively, with sensitivities /

28 specificities of 84.8% / 77.9%, 90.1% / 81.4%, 85.1% / 92.5% and 85.4% / 91.5% (Figure 1).

29 C-HRCT and U-HRCT image quality scoring

30 With respect to objective image quality scores, the SD in U-HRCT was greater than that of C-HRCT, and

31 the SNR was lower than that of C-HRCT; the difference was statistically significant (p < 0.05) (Table 2).

32 With increased iteration levels, SD decreased, and SNR increased. At the same iteration level, the SD of U-

HRCT was greater than that of C-HRCT, and the SNR was lower than that of C-HRCT. Pairwise

34 comparisons showed that there was no statistically significant difference in image quality between U-HRCT

using iDose5 iteration and C-HRCT using iDose3 conditions (p > 0.05).

The iDose⁴-5 iteration had the highest U-HRCT score for displaying the lesion structure and vascular structure of lung tissue. Except for display of lesion margins and crazy-paving patterns within the lesion, the differences in subjective scores were statistically significant (p < 0.05). Pairwise comparisons showed that the C-HRCT scores at high iteration levels were lower than those at low iteration levels for display of the internal structure of some lesions; there was no statistically significant difference between the two iteration

1 levels (p > 0.05). There was no statistically significant difference in subjective scores for display of air bronchograms between U-HRCT and C-HRCT (p > 0.05).

13 Discussion

COVID-19 is highly infectious and progresses rapidly. In severe cases, acute respiratory distress syndrome, respiratory failure, and even death may occur[9]. Diagnosis depends primarily on comprehensive consideration of epidemiology, clinical manifestations, and imaging and laboratory data. Chest CT, especially HRCT, is valuable in the diagnosis of suspected cases of COVID-19[10,11]. Although the imaging presentation of COVID-19 is similar to that of other viral pneumonias, the differential diagnosis is more difficult.However, COVID-19 could manifest some characteristic imaging signs, especially when ground-glass opacities werepresent[12,13].

51 In the confirmed COVID-19 cases in the present study, the lesions had a primarily subpleural distribution 52 and had a ground-glass appearance. Vascular thickening, air bronchograms, interlobular septal thickening, 53 and crazy-paving patterns were common in COVID-19 lesions. Air bronchograms were also common in 54 other pneumonias, and display of the bronchial walls is vital in the diagonise. The results of small-sample 55 binary logistic regression showed that the distribution of ground-glass lesions, vascular thickening, 56 interlobular septal thickening, and crazy-paving patterns have some value for diagnosing COVID-19. 57 COVID-19 could be more accurately diagnosed when taken together with the patient's epidemiological and radiological characteristics, which is generally consistent with the findings of previous studies[14]. 58

Display of the internal structure of ground-glass lesions is highly valuable for the diagnosis of COVID-19[15]. In practice, display of the internal details of these lesions is associated with the scanning technology used. U-HRCT uses a 1024 × 1024 matrix, allowing it to better display the morphological characteristics of pulmonary lesions[6,7,8]. Therefore, 1024 matrix U-HRCT images were retrospectively reconstructed and compared with C-HRCT in order to more accurately display the internal structure of ground-glass lesions and improve the accuracy of COVID-19 diagnosis. Compared to C-HRCT, U-HRCT has increased SD and decreased SNRin the present study.

In addition, iterative reconstruction techniques can also reduce SD and improve SNR[16-17].However, the reconstruction speed will be slower with higheriDose⁴iteration level, and the densities of the lesion and normal tissues tend to become homogeneous, which affects the observation of the internal structure of the lesion[18].Therefore, selection of an appropriate iteration level is essential.

⁷⁰ In the present study, the image quality of U-HRCT and C-HRCT with the iDose⁴-3 and iDose⁴-5 iterative ⁷¹ levels were compared and analyzed. We believe that the use of iDose⁴-5 iterative reconstruction can reduce ⁷² noise and improve image quality, as well as improve spatial and density resolution of images. Additionally, ⁷³ the reconstruction speed of iDose⁴-5 is suitable for clinical applications. The iDose⁴-5 iteration level has the ⁷⁴ highest U-HRCT score for displaying the lesion and vascular structures of the lung tissue; it is particularly ⁷⁵ suited for vascular thickening, interlobular septal thickening, and other signs in the internal structure of the ⁷⁶ lesion that are important for diagnosis (Figures 2–4).

77 There is no statistically significant difference between theC-HRCT and U-HRCT groups with respect to
78 displaying crazy-paving patterns. There may be subjective factors involved in the interpretation of signs
79 such as interlobular septal thickening and crazy-paving patterns.

This study had a few limitations. The number of patient samples included was small; consequently, statistical analysis may be biased. Retrospective target reconstruction was used in all cases, and no comparison with large-matrix U-HRCT target scan images was performed. Body mass index and radiation dose were not considered while evaluating image quality.

34 Conclusions

U-HRCT image could reduce noise and improve SNR with an increase of the iDose⁴level. The iDose⁴-5
level had the highest U-HRCT score for c1linical applications. Peripleural distribution, thickening of blood
vessels and interlobular septum, and crazy-paving pattern on U-HRCT are favorable signs for COVID-19.
U-HRCT is superior to C-HRCT in displaying the blood vessels, bronchial walls, and interlobular septum
for evaluating COVID-19.

)0 Declarations

}1	Ethics approval and consent to participate The retrospective study was approved by the Institutional
) 2	Review Board of Xiamen Universityand patients' written consent to participate or parents/guardians (for
) 3	anyone under the age of 16) was also obtained.
) 4	Consent to publishNot applicable.
) 5	Availability of data and materials The datasets analyzed during the current study are fully available from
) 6	the corresponding author on reasonable request. We confirmed that these patients have not yet been reported
) 7	in any other submission by the authors.
) 8	Competing interests The authors declare that they have no competing interests.
) 9	FundingNone.
) 9	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the
99)0)1	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or
€9 20 21 22	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or analysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revising
 Э9 Э0 Э1 Э2 Э3 	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or analysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revising it. critically for important intellectual content (ZWG and WJA), (3) final approval of the version to be
 99 00 01 02 03 04 	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or analysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revising it. critically for important intellectual content (ZWG and WJA), (3) final approval of the version to be submitted (LSM, LY, KJH , DSY, ZWG and WJA). Furthermore, each of the authors has read and concurs
 99 00 01 02 03 04 05 	FundingNone.Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) theconception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), oranalysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revisingit. critically for important intellectual content (ZWG and WJA), (3) final approval of the version to besubmitted (LSM, LY, KJH , DSY, ZWG and WJA). Furthermore, each of the authors has read and concurswith the content in the manuscript.
 Э9 Э0 Э1 Э2 Э3 Э4 Э5 Э6 	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or analysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revising it. critically for important intellectual content (ZWG and WJA), (3) final approval of the version to be submitted (LSM, LY, KJH , DSY, ZWG and WJA). Furthermore, each of the authors has read and concurs with the content in the manuscript. AcknowledgementsNot applicable.
 Э9 Э0 Э1 Э2 Э3 Э4 Э5 Э6 Э7 	FundingNone. Authors' ContributionsAll authors have made substantial contributions to all of the following: (1) the conception and design of the study (LSM, LY, KJH and ZWG), or acquisition of data (LSM andLY), or analysis and interpretation of data (DSY, WJA and LSM), (2) drafting the article (LSM andLY) or revising it. critically for important intellectual content (ZWG and WJA), (3) final approval of the version to be submitted (LSM, LY, KJH, DSY, ZWG and WJA). Furthermore, each of the authors has read and concurs with the content in the manuscript. AcknowledgementsNot applicable.

COVID-19: Corona-virus disease 2019

Abbreviations:

)8

- 10 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- 11 **HRCT:** High resolution computed tomography
- 12 **C-HRCT:** Conventional high resolution computed tomography
- 13 U-HRCT:Ultra high resolution computed tomography
- 14 **FOV:**Field of view
- **I5 ROI:** Region of interest
- **I6 SD:** Standard deviation
- 17 SNR:Signal-to-noise ratio
- 18 **ROC:**The receiver operating characteristic curve
- **19 AUC:** Area under the curve
- 20

21 References

- 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J].
- 23 N Engl J Med. 2020 Feb 20;382(8):727-733
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in
 Wuhan, China[J]. Lancet. 2020 Feb 15;395(10223):497-506.
- Xie C,Jiang L,Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by
 nucleic acid amplification tests[J]. Int J Infect Dis. 2020 Apr;93:264-267.
- TravisWD, BrambillaE, NoguchiM, et al. International association for the study of lung cancer/
 American thoracic society/European respiratory society: international multidisciplinary classification of
 lung adenocarcinoma-an executive summary[J]. Proc Am Thorac Soc. 2011 Sep;8(5):381-385.

- 31 5. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV).
- 32 Radiology. 2020 Apr;295(1):202-207
- Hata A, Yanagawa M, Honda O, et al. Effect of matrix size on the image quality of ultra-high-resolution
 CT of the lung: Comparison of 512×512,1024 ×1024, and 2048 ×2048. Acad Radiol. 2018
 Jul;25(7):869-876.
- 7. Zhu H, Zhang L, Wang Y,et al. Improved image quality and diagnostic potential using ultra-highresolution computed tomography of the lung with small scan FOV: A prospective study. PLoS One.
 2017 Feb 23;12(2):e0172688.
- 8. Yanyan Z, Dailun H, Meihong L, et al. A comparison of ultra-high-resolution CT target scan versus
 conventional CT target reconstruction in the evaluation of groundglass-nodule-like lung
 adenocarcinoma. Quant Imaging Med Surg. 2019 Jun;9(6):1087-1094
- 42 9. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus43 infected pneumonia[J]. N Engl J Med. 2020 Mar 26;382(13):1199-1207.
- 10. Hu L, Wang C. Radiological role in the detection, diagnosis and monitoring for the coronavirus disease
 2019 (COVID-19). Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4523-4528.
- 11. Luo L, Luo Z, Jia Y, et al. CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic
 suspects: a practical scoring method [J]. BMC Pulm Med. 2020 May 7;20(1):129.
- 12. Lei J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019nCoV) pneumonia. Radiology.
 2020 Apr;295(1):18.
- 50 13. Li X, Zeng W, Li X, et al.CT imaging changes of corona virus disease 2019(COVID-19): a multi-center
 51 study in Southwest China[J]. J Transl Med. 2020 Apr 6;18(1):154.
- 52 14. Shi H, Han X, Jiang N, et al., Radiological findings from 81 patients with COVID-19 pneumonia in
- 53 Wuhan, China: a descriptive study[J].. Lancet Infect Dis. 2020 Apr;20(4):425-434.

- 54 15. Zhao W, Zhong Z, Xie X et al. Relation Between Chest CT Findings and Clinical Conditions of
- 55 Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study[J]. AJR Am J Roentgenol. 2020
- 56 May;214(5):1072-1077.
- 57 16. Lim HJ, Chung MJ, Shin KE, et al. The Impact of Iterative Reconstruction in Low-Dose Computed
- 58 Tomography on the Evaluation of Diffuse Interstitial Lung Disease[J] . Korean J Radiol. 2016 Nov-
- 59 Dec;17(6):950-960.
- 50 17. Masahiro Yanagawa, Akinori Hata, Osamu Honda, et al. Subjective and objective comparisons of image
- 51 quality betweenultra-high-resolution CT and conventional area detector CT inphantoms and cadaveric
- 52 human lungs[J]. EurRadiol. 2018 Dec;28(12):5060-5068.
- 53 18. de Boer E, Nijholt IM, Jansen S, et al. Optimization of pulmonary emphysema quantification on CT
- 54 scans of COPD patients using hybrid iterative and post processing techniques: correlation with
- 55 pulmonary function tests[J]. Insights Imaging, 2019, 10 (1): 102.

56



57



Fig. 1 ROC curve of lesion distribution, density, and internal structure



70

′1 (a)



- 72
- 73 (b)

⁷⁴ Fig. 2 Coronal reconstruction of (a) C-HRCT and(b) U-HRCT images of a female 43-year-old patient
⁷⁵ with COVID-19.Bronchial walls and crazy-paving patterns are clearly displayed inU-HRCT but not
⁷⁶ clearly displayed inC-HRCT



78

79 (a)



31 (b)

Fig. 3(a) C-HRCT and (b) U-HRCT images of a male 38-year-old patient with COVID-19. Crazypaving patterns, interlobular septal thickening, air bronchograms, and smooth bronchial margins are

34 clearly displayed onU-HRCT image



37	Fig. 4 C-HRCT and (b) U-HRCT images of a female 55-year-old patient with COVID-19. Air
38	bronchograms, smooth bronchial marginsin the lesion are clearly displayed in U-HRCT

- 39
-)0
- **}1**
-)2
-)3
-)4
-)5
-)6

Table 1 Analysis of CT signs of COVID-19 and non- COVID-19 lesions

	Classification	COVID-19	non-COVID-19	χ^2	<i>p</i> -value	
	Pure ground-glass opacity	12 (75%)	12 (20.34%)			
Lesion density	Mixed ground-glass opacity	3 (18.75%)	38 (64.41 %)	12.191	0.000	
	Consolidation	1 (6.25%)	9 (15.25%)			
Lesion	≤2 cm from pleura	14 (87.5%)	6 (10.17%)	28.40	0.000	
distribution	> 2 cm from pleura	2 (12.5%)	53 (89.83%)	38.49	0.000	
Lesion	Multiple	9 (56.25%)	30 (50.85%)	0.147	0.701	
number	Single	7 (43.75%)	29 (49.15%)	0.147	0.701	
Internal	Vascular thickening	14 (87.5%)	8 (13.56%)	33.197	0.000	
structure of	Air bronchograms	13 (81.25%)	25 (42.37 %)	7.611	0.000	
lesions	Interlobular septa thickening	13 (81.25%)	11 (18.64 %)	22.672	0.000	
	Crazy-paving patterns	15 (93.75%)	5 (8.47%)	46.805	0.000	

)8

39 Table 2 Logistic regression analysis of CT signs of COVID-19

Indicator	B-value	OR (95%CI)	<i>p</i> -value
Lesion distribution	-4.508	0.011 (0.0006,0.216)	0.003
Lesion density	-1.114	0.3289 (0.054,1.990)	0.226
Vascular thickening	3.766	43.213 (2.677,697.430)	0.008
Air bronchograms	2.235	9.342 (0.675,129.208)	0.095
Interlobular septa thickening	3.257	25.9615 (1.589,424.151)	0.022
Crazy-paving pattern	5.553	258.081 (16.502,4036.160)	0.000

)0

)1

)2

)3

)4

Table 3 C-HRCT and U-HRCT image quality evaluation

		Cases	512 × 512		1024×1024		F	P
		(n)	iDose ⁴ -3	iDsoe ⁴ -5	iDose ⁴ -3	iDose ⁴ -5	1	Ĩ
	Noise (HU)	75	74.63 ±18.11	60.06 ± 18.04	95.12±14.16	79.64 ±13.99	56.569	0.000
Sign	Signal-to-noise ratio		12.48 ±3.15	15.53 ±4.33	9.44 ±1.73	11.31 ± 2.30	50.067	0.000
Overa	Overall subjective score		4.59±0.50	4.28±0.72	4.10±0.59	4.79±0.41	21.152	0.000
Bronch	Bronchovascular display		3.49±0.77	3.51±0.83	3.96±0.57	4.21±0.75	16.279	0.000
L	Lesion display		4.36±0.61	4.27±0.72	4.43±0.64	4.80±0.40	11.21	0.000
Lesio	n margins display	75	4.36±0.67	4.25±0.72	4.22±0.61	4.44±0.74	1.551	0.201
	Air bronchograms	38	4.57±0.50	4.25±0.72	4.24±0.59	4.79±0.41	8.338	0.000
Display	Crazy-paving sign	18	4.17±0.62	4.28±0.67	4.44±0.62	4.67±0.49	2.359	0.079
of	Vessel	22	4.41±0.58	4.45±0.60	4.81±0.50	4.89±0.35	5.057	0000
internal	Bronchial wall	43	4.37±0.69	4.27±0.73	4.49±0.55	4.86±0.35	7.757	0.000
structure	Interlobular septa	24	4.48±0.50	4.21±0.78	4.79±0.41	4.83±0.38	6.652	0.000

)6

)7